We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

By LabMedica International staff writers
Posted on 29 Oct 2024
Print article
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that can arise in areas such as the mouth, throat, larynx, nose, sinuses, and salivary glands. Major risk factors include tobacco and alcohol consumption, both of which considerably heighten the likelihood of developing these cancers. Additionally, infections with the human papillomavirus (HPV) are becoming increasingly significant, particularly in certain cases of throat cancer. The five-year survival rate for head and neck cancers ranges from 40% to 70%, with different subtypes exhibiting varied prognoses. Now, a novel technology combines indicators of cancer cell behavior with the architecture of the tumor and adjacent healthy tissue to create a unique ‘fingerprint’ for each patient, aiding in prognosis assessment and response evaluation to cancer therapy.

Utilizing a machine-learning-based approach, a collaborative team of researchers from the University of Helsinki (Helsinki, Finland), the University of Turku (Turku, Finland), and the Max Planck Institute for Molecular Biomedicine (Münster, Germany) analyzed hundreds of biobank patient samples at the single-cell level. A key finding from this study was the introduction of a new imaging technique that merges the analysis of biomarkers related to cell behavior with morphological assessments of individual cell shapes and the overall tumor tissue structure. This innovative method successfully identified two previously unknown patient groups: one with an exceptionally favorable prognosis and another with a notably poor prognosis. The distinction between these groups was attributed to a specific combination of a particular cancer cell state and the makeup of the tissue surrounding the cancer cells.

In the group with poor outcomes, the disease's aggressiveness was associated with signaling between the cancerous tissue and the adjacent healthy connective tissue, mediated by the epidermal growth factor (EGF). This new imaging technique paves the way for precision diagnostics in head and neck cancers. The researchers are now working on developing a diagnostic test aimed at achieving more accurate diagnoses for this type of cancer. Furthermore, they are exploring the applicability of this method in diagnosing other cancer types, including colon cancer.

“Our research uses the latest analytical methods in machine learning and spatial biology. We analyze hundreds of patient samples and millions of cells, which is only possible with the help of high-performance computing and artificial intelligence. This study is part of a new revolution in cancer diagnostics. We believe that the technology will significantly improve cancer diagnostics and the accuracy of treatment strategies,” said Sara Wickström from the University of Helsinki who led the research team. “Imaging of cancer biomarkers with antibody staining is already in clinical use. Therefore, the method will not be particularly expensive, as it only requires the algorithm we have developed and a special combination of antibodies. Considering the cost of cancer treatment, it is actually quite affordable.” The researchers' findings were published online October 28 in the journal Cell.

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.